# A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors

> **NCT05150405** · PHASE1 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 54 (estimated)

## Conditions studied

- Solid Tumor
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** QLF31907

## Key facts

- **NCT ID:** NCT05150405
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-19
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-06-01
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05150405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05150405, "A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05150405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*